Banner for leaf pages 2

Abatacept (Orencia)

Also known as Orencia

Abatacept (marketed as Orencia) is a fusion protein composed of the Fc region of the immunoglobulin IgG1 fused to the extracellular domain of CTLA-4. It is a molecule capable of binding with more avidity to CD80 (B7-1) than to CD86 (B7-2). Abatacept is a selective co-stimulation modulator as it inhibits the costimulation of T cells. It was developed by Bristol-Myers Squibb and is licensed in the United States for the treatment of rheumatoid arthritis in the case of inadequate response to anti-TNFα therapy.

Source: Wikipedia

Estimated Total Cost: $1752.87 for an average of 28 days supply

What is it prescribed for?

Patients are most commonly prescribed abatacept to treat rheumatoid arthritis, osteoarthritis, heart attack, and rabies.

What drug interactions are known?

Do not take abatacept if you are taking any of the following:

Critical Interactions

Significant Interactions


Ajax-loader Loading...